^
    5ms
    A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Beth Israel Deaconess Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    decitabine • GO-203-2c
    almost2years
    A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jul 2023
    Trial completion date • Trial primary completion date
    |
    MUC1 (Mucin 1)
    |
    MUC1 overexpression
    |
    decitabine • GO-203-2c
    almost3years
    A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    MUC1 (Mucin 1)
    |
    MUC1 overexpression
    |
    decitabine • GO-203-2c
    3years
    A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    MUC1 (Mucin 1)
    |
    MUC1 overexpression
    |
    decitabine • GO-203-2c
    over3years
    A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jul 2020 --> Dec 2020
    Clinical • Trial primary completion date
    |
    MUC1 (Mucin 1)
    |
    MUC1 overexpression
    |
    decitabine • GO-203-2c
    almost4years
    A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Nov 2019 --> Jul 2020
    Clinical • Trial primary completion date
    |
    MUC1 (Mucin 1)
    |
    MUC1 overexpression
    |
    decitabine • GO-203-2c